PetIQ Inc (PETQ)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Why Fast-paced Mover PetIQ (PETQ) Is a Great Choice for Value Investors
PetIQ (PETQ) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts See a 40.44% Upside in PetIQ (PETQ): Can the Stock Really Move This High?
The consensus price target hints at a 40.4% upside potential for PetIQ (PETQ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Investors Undervaluing PetIQ (PETQ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Despite Fast-paced Momentum, PetIQ (PETQ) Is Still a Bargain Stock
PetIQ (PETQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Natixis Advisors L.P. Increases Position in PetIQ, Inc. (NASDAQ:PETQ)
Natixis Advisors L.P. lifted its position in shares of PetIQ, Inc. (NASDAQ:PETQ – Free Report) by 10.2% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 12,038 shares of the company’s stock after buying an additional 1,113 shares during the period. Natixis Advisors L.P.’s holdings in PetIQ were worth $237,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also modified their holdings of PETQ. DekaBank Deutsche Girozentrale acquired a new position in PetIQ during the fourth quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. increased its position in PetIQ by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,372 shares of the company’s stock worth $67,000 after purchasing an additional 2,625 shares during the last quarter. UBS Group AG increased its position in PetIQ by 0.9% during the third quarter. UBS Group AG now owns 400,488 shares of the company’s stock worth $7,890,000 after purchasing an additional 3,382 shares during the last quarter. SG Americas Securities LLC increased its position in PetIQ by 75.1% during the fourth quarter. SG Americas Securities LLC now owns 10,054 shares of the company’s stock worth $199,000 after purchasing an additional 4,311 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in PetIQ by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,914 shares of the company’s stock worth $4,017,000 after purchasing an additional 7,309 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock. PetIQ Price Performance PETQ opened at $19.97 on Monday. The company has a fifty day simple moving average of $17.41 and a 200 day simple moving average of $18.02. The firm has a market cap of $587.74 million, a price-to-earnings ratio of 90.77 and a beta of 1.68. PetIQ, Inc. has a twelve month low of $12.19 and a twelve month high of $22.98. The company has a current ratio of 2.42, a quick ratio of 1.25 and a debt-to-equity ratio of 1.84. PetIQ (NASDAQ:PETQ – Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.22. The business had revenue of $219.93 million during the quarter, compared to analyst estimates of $189.70 million. PetIQ had a net margin of 0.66% and a return on equity of 13.33%. Equities research analysts expect that PetIQ, Inc. will post 1.09 EPS for the current fiscal year. Wall Street Analysts Forecast Growth Several equities research analysts have recently issued reports on PETQ shares. Benchmark reissued a “buy” rating and issued a $30.00 price objective on shares of PetIQ in a research report on Friday, May 10th. Jefferies Financial Group increased their price objective on shares of PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $29.00. View Our Latest Analysis on PetIQ PetIQ Company Profile (Free Report) PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats. See Also Five stocks we like better than PetIQ Using the MarketBeat Stock Split Calculator MarketBeat Week in Review – 5/13 – 5/17 3 Small Caps With Big Return Potential Take-Two Interactive Software Offers 2nd Chance for Investors Most active stocks: Dollar volume vs share volume Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
